Skip to main content
Figure 5 | Molecular Medicine

Figure 5

From: Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells

Figure 5

T1E28z engineered T cells are activated by human head and neck cancer cells. (A) Confluent head and neck tumor monolayers (24-well plate, 1.9 cm2) were cocultivated with 1 × 106 of the indicated T-cell populations. Supernatants were harvested after 72 h and analyzed for IFN-γ (mean ± SD). The number of independent replicate experiments is indicated: *** P < 0.001, **P < 0.01, *P < 0.05. (B) Engineered T cells were cocultivated with HN3 tumor cell monolayers where indicated by overhead arrows. T cells were enumerated at specified intervals. (C) T cells in (B) were analyzed by FACS for cell surface expression of T1E28z at the indicated time points. Untransduced T cells served as the negative control. (D) Engineered T cells were stimulated on a HN3 monolayer and cultured in the presence of IL-2. Control cultures were maintained in IL-2 alone without monolayer stimulation. Cultures were analyzed for CAR expression using monoclonal anti-EGF antibody at baseline and after 7 d. Filled histograms show staining of untransduced T cells. Proliferation/enrichment data are representative of at least three experiments.

Back to article page